Trading Sections

Rezolute: Wedbush Raises Price Target After upLIFT Study Data - Experts See 173% Price Potential!

Wedbush sets a price target for Rezolute (RZLT) at 10 USD after positive Phase 3 data for Ersodetug....

Rocket Pharmaceuticals: How Danon Studies Drive Valuation Levels - Experts See Up to 422% Price Potential!

Focus on AAV-based gene therapies for rare diseases, with Danon disease as the primary pipeline driver....

PTC Therapeutics: Will the Long-Term Market Penetration with the Drug Sephience Succeed? Experts See 74% Price Potential!

The biotechnology company PTC Therapeutics is benefiting from robust revenue growth driven by the drug...

Replimune: Leerink Analyst Sees Over 80% Price Potential After Quarterly Results

Replimune undergoes a transformation into a commercial company focused on the oncology product TUDRIQEV....

C4 Therapeutics: $11 Price Target from Lake Street Highlights Triple Strategy in Multiple Myeloma

C4 Therapeutics utilizes targeted protein degradation for cancer treatment and advances the clinical...

Immunome: Regulatory filings and new study data - H.C. Wainwright sees 112% price potential!

ESMO data demonstrate sustainable relief in aggressive desmoid tumors. Analysts see a price target...

Corcept Therapeutics: FDA Decision in December - The Catalyst for the $165 Price Target?

Analysts at Piper Sandler confirm the buy recommendation for Corcept Therapeutics with a price target...

Ionis Pharmaceuticals: Is the RNA specialist poised for a growth phase thanks to Tryngolza potential?

Citi analyst Eric Joseph confirms a price target of Ionis Pharmaceuticals (IONS) of 100 USD and considers...

Climb Bio: Deutsche Bank Identifies Entry Opportunity in Biotech Stock with $28 Price Target

Price target of $28: Why Deutsche Bank currently sees an upside potential of about 185% for Climb Bio....

Annexon: ARCHER-II Readout and GBS Approval - H.C. Wainwright Raises Price Target to 25 USD!

H.C. Wainwright considers the stock of Annexon (ANNX) (i.) to be significantly undervalued and raises...

EchoStar: How the $43 Billion Frequency Deal with SpaceX and AT&T is Realigning the Company

JPMorgan has upgraded the stock of EchoStar (ECHO) to "Overweight" and sees the price target at $144....

Digital Turbine: AI Integration and App Growth Boost Margins - Roth Capital Sees Potential for Doubling Stock Price!

App monetization and AI-driven automation are accelerating the structural growth of Digital Turbine (APPS)...

Sol-Gel Technologies: Topical Skin Cancer Inhibitor in Focus of Wall Street

Cantor Fitzgerald rates the stock as "Overweight" with a target of $200. The analyst points to an attractive...

Electra Therapeutics: Is a price target of 32 USD paving the way for the first FDA approval for mHLH?

The business model focuses on SIRP immunotherapies for inflammatory and oncological diseases. Jefferies...

Nektar Therapeutics: 4.0 Billion USD Revenue Potential – Why a New Biologic Drives the Price Target to 130 USD

Leerink analyst assigns an "Outperform" rating with an ambitious price target of 130 USD for Nektar Therapeutics...

TeraWulf: The Billion-Dollar Infrastructure Transformation for the AI Sector - Morgan Stanley Raises Price Target to $65!

The focus on high-performance computing (HPC) and AI infrastructure fundamentally expands the business...

Vir Biotechnology: FDA Fast Track Status and New Clinical Data as Potential Price Drivers - Barclays Sets Target at $30!

Vir Biotechnology (VIR) focuses on combating infectious diseases and cancer through the human immune...

Chewy Inc.: Analysts from Morgan Stanley see 100% price potential in the subscription model!

Morgan Stanley confirms the buy recommendation for Chewy Inc. (CHWY) with a price target of $36, supported...

Compass Inc.: Anywhere Merger Sparks New Market Enthusiasm - Barclays Sees 70% Price Potential

The technology-based business model of Compass Inc. (COMP) significantly benefits from market consolidation...

Ondas: Drone Defense and Acquisitions Drive the Value of the Autonomy Platform - Citizens Announces $14 Price Target!

Citizens Research has Ondas Inc. (ONDS) initiated coverage on October 5 with an "Outperform" rating...

LB Pharmaceuticals: Targeting a Multibillion-Dollar Market – How a Modified Drug Could Transform Psychiatry

LB Pharmaceuticals (LBRX) is pursuing a new therapeutic approach. LB-102 addresses schizophrenia and...

Kura Oncology: Insider Purchases and Pipeline Expansion as a Catalyst for JPMorgan's $30 Price Target

Kura Oncology (KURA) is making a strategic shift to become a commercial cancer therapeutic provider....

Uranium Energy: Focus on North American Uranium Production Convincing Experts from H.C. Wainwright!

Uranium Energy (UEC) focuses on environmentally friendly in-situ recovery to build a domestic supply...